New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma

J Clin Oncol. 2015 Apr 10;33(11):e52-6. doi: 10.1200/JCO.2013.51.5783. Epub 2014 May 12.

Authors

Affiliations

¹ Westmead Institute for Cancer Research, University of Sydney at Westmead; Millennium Institute; Westmead Hospital, Sydney, Australia.
² Westmead Hospital, Sydney, Australia.
³ Queensland Centre for Medical Genomics; Institute of Molecular Bioscience, University of Queensland, St Lucia, Brisbane, Australia.
⁴ Canberra Hospital and Australian National University Medical School, Canberra, Australia.
⁵ The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia.
⁶ Melanoma Institute Australia; Royal Prince Alfred Hospital, Sydney, Australia.
⁷ Westmead Institute for Cancer Research, University of Sydney at Westmead; Millennium Institute; Westmead Hospital; Melanoma Institute Australia, Sydney, Australia.
⁸ The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney; South Western Sydney Clinical School, University of New South Wales, Liverpool, Australia; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow; Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom.
⁹ Melanoma Institute Australia; The University of Sydney and Westmead Institute for Cancer Research, Sydney, Australia [email protected].

PMID: 24821886
DOI: 10.1200/JCO.2013.51.5783

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / chemically induced*
Adenocarcinoma / drug therapy
Adenocarcinoma / enzymology
Adenocarcinoma / genetics
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Biopsy
DNA Mutational Analysis
Humans
Imidazoles / administration & dosage
Imidazoles / adverse effects
Immunohistochemistry
MAP Kinase Kinase Kinases / antagonists & inhibitors*
MAP Kinase Kinase Kinases / metabolism
Male
Melanoma / drug therapy*
Melanoma / enzymology
Melanoma / genetics
Melanoma / secondary*
Middle Aged
Molecular Targeted Therapy
Mutation*
Oximes / administration & dosage
Oximes / adverse effects
Pancreatic Neoplasms / chemically induced*
Pancreatic Neoplasms / drug therapy
Pancreatic Neoplasms / enzymology
Pancreatic Neoplasms / genetics
Positron-Emission Tomography
Predictive Value of Tests
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics
Proto-Oncogene Proteins B-raf / metabolism
Proto-Oncogene Proteins p21(ras)
Pyridones / administration & dosage
Pyridones / adverse effects
Pyrimidinones / administration & dosage
Pyrimidinones / adverse effects
Risk Factors
Skin Neoplasms / drug therapy*
Skin Neoplasms / enzymology
Skin Neoplasms / genetics
Skin Neoplasms / pathology*
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
ras Proteins / genetics*

Substances

Imidazoles
KRAS protein, human
Oximes
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Pyridones
Pyrimidinones
trametinib
BRAF protein, human
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase Kinases
Proto-Oncogene Proteins p21(ras)
ras Proteins
dabrafenib

Grants and funding